Parexel, a leading global clinical research organization (CRO), has appointed Jim Anthony as chief commercial officer (CCO) and president of Parexel Biotech, expanding his responsibilities to strengthen the company’s customer focus and accelerate growth.

Anthony has been with Parexel since 2010, serving in multiple leadership roles across business development and biotech. Since the inception of Parexel Biotech in 2019, he has been its global leader and was promoted to president and global head in 2023. Under his leadership, the biotech unit has grown to contribute nearly half of Parexel’s global revenue.

“With clinical development evolving rapidly, our ability to innovate for customers is more critical than ever,” said Peyton Howell, CEO of Parexel. “Jim is the ideal leader to expand our commercial strategy, given his proven track record in building Parexel Biotech. His vision and expertise will help scale this success across our global organization.”

As part of succession planning, Conal Burgess, president and global head of Enterprise Partnerships, will step down from Parexel on December 31, 2025.

In his expanded role, Anthony will oversee customer strategy and partnerships globally, across both biotech and pharmaceutical sectors, leveraging Parexel’s expertise in phase I–IV clinical development to help accelerate life-changing therapies to market.